Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2011

View Archived Issues

Long-term daclizumab therapy analyzed in patients with MS

Phosphodiesterase 5 inhibitor improves portal hypertension in open-label trial

Boceprevir improves hepatitis C treatment in patients coinfected with HIV

Ondansetron is effective in treating diarrhea-predominant irritable bowel syndrome

Telormedix reports promising preclinical data on topical skin cancer treatment

Clinuvel's Scenesse shows clinically relevant prophylactic effect in EPP

Chelsea Therapeutics reports interim results from phase II study of CH-4051

New mTOR inhibitors disclosed by Auspex Pharmaceuticals

RespiVert prepares novel MAP kinase p38 inhibitors

Life Sciences Research Partners and Flanders' VIB claim new cell-based ischemia therapy

Tibotec presents novel HIV integrase inhibitors

Senesco initiates dosing in phase Ib/IIa SNS01-T study

Tetraphase Pharmaceuticals synthesizes new antibacterial agents

Avanir Pharmaceuticals enrolls first patient in PRIME study

Optimer files NDS for Dificid in Canada

Interim analysis of MDV-3100 prostate cancer study shows beneficial survival data

BMS and Aslan enter agreement for anticancer compound

RedHill Biopharma plans RHB-102 bioequivalence study

Korean company patents new glucagon GLP-1 receptor agonists

Novel casein kinase II inhibitors reported by BMS

Researchers at Lilly describe novel cannabinoid CB2 receptor agonists

PharmaGap plans in vivo efficacy testing of GAP-107B8

FDA accepts VIVUS' resubmitted Qnexa NDA

Atlab Pharma and BZL Biologics enter licensing agreement for [177Lu]-J591

Discovery Labs' lucinactant gains European orphan drug status

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...